What are we trying to treat?
Describe the concern in ordinary words. Ask what the doctor thinks is causing it, what remains unclear and what would help settle the question.
What are the other choices?
Ask what care fits the problem, what each option aims to change and how you would judge progress. Ask what happens if you choose no treatment for now.
Does this substance have drug approval?
The FDA, which oversees US medicines, had approved no medical use for BPC-157 as of September 28, 2026.
Ask how that affects the proposed care and what rule the offer relies on. Ask for the evidence rather than a badge.
Which ingredient, made by whom?
Different substances can be sold using the same name, BPC-157. Here the difference means the ingredient itself changes. It does not mean simply putting the same ingredient into a pill instead of an injection. The FDA warns this can mean receiving a different substance from the one ordered (review checked September 28, 2026).
Ask for the exact ingredient name and the pharmacy’s name. Ask who takes responsibility for answering questions about what is supplied.
What does the batch test actually show?
A batch is a group made at the same time. Purity means the share of a sample that is the named substance.
Most BPC-157 test reports the FDA examined gave a purity figure. They did not say how much of other substances was found, or how much was allowed (review checked September 28, 2026). This missing information does not tell you whether those tests were done.
The FDA review also names separate safety checks for injections: germs, tiny stray particles and poisons made by bacteria.
Ask the doctor to explain the report and its limits in words you understand.
What happens after this visit?
Ask who reviews progress, who answers a concern and when another assessment would be needed. Get the visit fee and follow-up terms in writing.